BioMedWorks’ Newsletter

BioMedWorks’ Newsletter

Share this post

BioMedWorks’ Newsletter
BioMedWorks’ Newsletter
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver disease

FDA approves Madrigal’s NASH drug, marking…

BioMedWorks
Mar 14, 2024
3

Share this post

BioMedWorks’ Newsletter
BioMedWorks’ Newsletter
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver disease

This thyroid hormone analogue, resmetirom, gets marketing approval.

Read →
Comments
User's avatar
© 2025 BioMedWorks LLC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share